MultiCell Technologies, Inc. (MCET) |
1.0E-5 0 (900%) 05-14 12:59 |
Open: | 1.0E-5 |
High: | 1.0E-5 |
Low: | 1.0E-5 |
Volume: | 20,000 |
Market Cap: | 1(M) |
PE Ratio: | 0 |
Exchange: | Other OTC |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | |
Resistance 1: | |
Pivot price: | |
Support 1: | |
Support 2: | |
52w High: | 0.0001 |
52w Low: | 1.0E-5 |
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
EPS | |
Book Value | |
PEG Ratio | |
Gross Profit |
Profit Margin (%) | |
Operating Margin (%) | |
Return on Assets (ttm) | |
Return on Equity (ttm) |
Wed, 17 Feb 2021
MCET Stock: 6 Things to Know About Biopharma MultiCell Technologies as Shares Blast Higher - InvestorPlace
Thu, 16 May 2024
Thu, 16 May 2024
Thu, 16 May 2024
Thu, 16 May 2024
Thu, 16 May 2024
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |